Clinical Trial Update: Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating tolerability, safety, and pharmacokinetics of four single doses of BIA 6-512 (trans-resveratrol) and its effect on levodopa pharmacokin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 6-512 (trans-resveratrol) (trans-resveratrol)
• levodopa (levodopa)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED